James Mulshine to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications James Mulshine has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
3.008
-
Shared decision making and screening: an ongoing dialogue informed by data. Oncology (Williston Park). 2015 Mar; 29(3):149.
Score: 0.402
-
hnRNP A2/B1 modulates epithelial-mesenchymal transition in lung cancer cell lines. Cancer Res. 2010 Sep 15; 70(18):7137-47.
Score: 0.294
-
Cytokines and growth factors stimulate hyaluronan production: role of hyaluronan in epithelial to mesenchymal-like transition in non-small cell lung cancer. J Biomed Biotechnol. 2010; 2010:485468.
Score: 0.291
-
Clinical issues in the management of early lung cancer. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4993s-4998s.
Score: 0.206
-
Surgical considerations with lung cancer screening. J Surg Oncol. 2003 Sep; 84(1):1-6.
Score: 0.181
-
Screening for lung cancer: in pursuit of pre-metastatic disease. Nat Rev Cancer. 2003 Jan; 3(1):65-73.
Score: 0.173
-
Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer. Clin Cancer Res. 1999 Nov; 5(11):3385-93.
Score: 0.139
-
Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. Exp Lung Res. 1998 Jul-Aug; 24(4):617-28.
Score: 0.127
-
Integrated clinical and basic studies related to circumventing non-small cell lung cancer drug resistance. Lung Cancer. 1994 Mar; 10 Suppl 1:S73-81.
Score: 0.094
-
Initiators and promoters of lung cancer. Chest. 1993 Jan; 103(1 Suppl):4S-11S.
Score: 0.087
-
A phase II trial of carboplatin (CBDCA) in small-cell and non-small-cell lung cancer with correlation to in vitro analysis of cytotoxicity. Am J Clin Oncol. 1990 Aug; 13(4):285-9.
Score: 0.073
-
Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J Clin Oncol. 1988 Nov; 6(11):1685-93.
Score: 0.065
-
Treatment of non-small-cell lung cancer. J Clin Oncol. 1986 Nov; 4(11):1704-15.
Score: 0.056
-
Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. J Thorac Oncol. 2006 Nov; 1(9 Suppl):S20-6.
Score: 0.056
-
Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement. Clin Cancer Res. 2005 Jul 01; 11(13 Pt 2):4981s-4983s.
Score: 0.051
-
Clinical practice. Lung cancer screening. N Engl J Med. 2005 Jun 30; 352(26):2714-20.
Score: 0.051
-
Screening of mutations in the ras family of oncogenes by polymerase chain reaction-based ligase chain reaction. Methods Mol Med. 2003; 74:187-200.
Score: 0.043
-
Expression of early lung cancer detection marker: hnRNP-A2/B1 and its relation to microsatellite alteration in non-small cell lung cancer. Lung Cancer. 2001 Dec; 34(3):341-50.
Score: 0.040
-
Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res. 1998 Mar-Apr; 18(2A):775-82.
Score: 0.031
-
Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin Cancer Res. 1997 Dec; 3(12 Pt 1):2237-46.
Score: 0.030
-
High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clin Cancer Res. 1997 Mar; 3(3):479-82.
Score: 0.029
-
Lung cancer: current therapies and new targeted treatments. Lancet. 2017 01 21; 389(10066):299-311.
Score: 0.028
-
Purification and characterization of a protein that permits early detection of lung cancer. Identification of heterogeneous nuclear ribonucleoprotein-A2/B1 as the antigen for monoclonal antibody 703D4. J Biol Chem. 1996 May 03; 271(18):10760-6.
Score: 0.027
-
Expression of early lung cancer detection marker p31 in neoplastic and non-neoplastic respiratory epithelium. Lung Cancer. 1996 Feb; 14(1):85-97.
Score: 0.027
-
Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl. 1996; 24:173-85.
Score: 0.027
-
Monoclonal antibody alpha IR-3 inhibits non-small cell lung cancer growth in vitro and in vivo. J Cell Biochem Suppl. 1996; 24:269-75.
Score: 0.027
-
Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. J Natl Cancer Inst. 1995 May 17; 87(10):756-61.
Score: 0.025
-
The early detection of second primary lung cancers by sputum immunostaining. LCEWDG Investigators. Lung Cancer Early Detection Group. Chest. 1994 Dec; 106(6 Suppl):385S-390S.
Score: 0.025
-
RB protein status and clinical correlation from 171 cell lines representing lung cancer, extrapulmonary small cell carcinoma, and mesothelioma. Oncogene. 1994 Sep; 9(9):2441-8.
Score: 0.024
-
Relationship of p53 overexpression and up-regulation of proliferating cell nuclear antigen with the clinical course of non-small cell lung cancer. Cancer Res. 1994 May 01; 54(9):2496-503.
Score: 0.024
-
Pre-operative and post-operative treatments in stage III NSCLC. Lung Cancer. 1994 Mar; 10 Suppl 1:S15-7.
Score: 0.023
-
Atrial natriuretic factor and arginine vasopressin production in tumor cell lines from patients with lung cancer and their relationship to serum sodium. Cancer Res. 1993 Jan 01; 53(1):67-74.
Score: 0.022
-
Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg. 1992 Jun; 53(6):992-8.
Score: 0.021
-
Peripheral airway cell marker expression in non-small cell lung carcinoma. Association with distinct clinicopathologic features. Am J Clin Pathol. 1992 Feb; 97(2):233-43.
Score: 0.020
-
p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene. 1992 Jan; 7(1):171-80.
Score: 0.020
-
Association between histological type and neuroendocrine differentiation on drug sensitivity of lung cancer cell lines. J Natl Cancer Inst Monogr. 1992; (13):191-6.
Score: 0.020
-
Expression of surfactant-associated protein in non-small-cell lung cancer: a discriminant between biologic subsets. J Natl Cancer Inst Monogr. 1992; (13):61-6.
Score: 0.020
-
ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res. 1991 Sep 15; 51(18):4999-5002.
Score: 0.020
-
Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene. 1991 Aug; 6(8):1353-62.
Score: 0.020
-
Nonrandom structural and numerical chromosome changes in non-small-cell lung cancer. Genes Chromosomes Cancer. 1991 May; 3(3):168-88.
Score: 0.019
-
Biological, molecular, and clinical markers for the diagnosis and typing of lung cancer. Immunol Ser. 1990; 53:453-68.
Score: 0.018
-
Autocrine growth loops dependent on peptidyl alpha-amidating enzyme as targets for novel tumor cell growth inhibitors. Lung Cancer. 1999 Mar; 23(3):209-22.
Score: 0.008
-
Detection of K-ras oncogene mutations by polymerase chain reaction-based ligase chain reaction. Anal Biochem. 1996 Aug 01; 239(2):153-9.
Score: 0.007
-
Insulin-like growth factor expression in human cancer cell lines. J Biol Chem. 1996 May 10; 271(19):11477-83.
Score: 0.007
-
Expression of carcinoembryonic antigen and related genes in lung and gastrointestinal cancers. Int J Cancer. 1992 Nov 11; 52(5):718-25.
Score: 0.005
-
Neuroendocrine differentiation in endocrine and nonendocrine lung carcinomas. Am J Clin Pathol. 1988 Dec; 90(6):641-52.
Score: 0.004